Antibacterial activity of co-trimazine in vitro and in vivo. 1979

B Ekström, and H Fellner, and U Forsgren, and L Magni, and B Ortengren

Co-trimazine is a new drug combination especially designed for the treatment of urinary tract infections. It consists of trimethoprim (90 mg) and sulphadiazine (410 mg). When combined in vitro, the components show high activity and a high frequency of synergy against urinary tract pathogens. After oral absorption sulphadiazine has a serum half-life similar to that of trimethoprim and is excreted in active form into the urine to a much higher degree than sulphamethoxazole. The ratio of the concentrations of trimethoprim and sulphadiazine in the urine following co-trimazine is favourable for a strong synergistic action between the compounds. In cross-over studies in volunteers receiving repeated daily doses of co-trimazine, either 500 mg twice daily or 1000 mg once daily, it was found that antibacterial activity in the urine was at least as high as that provided by co-trimoxazole (2 x 960 mg) and considerably higher and more uniform than that given by nitrofurantion (3 x 50 mg).

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009582 Nitrofurantoin A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression. Furadantin,Furadantine,Furadoine,Furadonine,Furantoin,Macrodantin,Nitrofurantoin Sodium Salt,Nitrofurantoin, Monohydrate
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000042 Absorption The physical or physiological processes by which substances, tissue, cells, etc. take up or take in other substances or energy.
D013411 Sulfadiazine One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections. Sulfazin,Sulfazine,Sulphadiazine,Zinc Sulfadiazine,Sulfadiazine, Zinc

Related Publications

B Ekström, and H Fellner, and U Forsgren, and L Magni, and B Ortengren
January 1986, Clinical pharmacokinetics,
B Ekström, and H Fellner, and U Forsgren, and L Magni, and B Ortengren
January 1977, Chemotherapy,
B Ekström, and H Fellner, and U Forsgren, and L Magni, and B Ortengren
January 1980, Clinical therapeutics,
B Ekström, and H Fellner, and U Forsgren, and L Magni, and B Ortengren
September 1967, Antibiotica,
B Ekström, and H Fellner, and U Forsgren, and L Magni, and B Ortengren
January 2014, Chinese medical journal,
B Ekström, and H Fellner, and U Forsgren, and L Magni, and B Ortengren
January 1979, Infection,
B Ekström, and H Fellner, and U Forsgren, and L Magni, and B Ortengren
January 1979, Infection,
B Ekström, and H Fellner, and U Forsgren, and L Magni, and B Ortengren
May 1997, The Journal of antimicrobial chemotherapy,
B Ekström, and H Fellner, and U Forsgren, and L Magni, and B Ortengren
January 1977, Proceedings of the Royal Society of Medicine,
B Ekström, and H Fellner, and U Forsgren, and L Magni, and B Ortengren
July 1983, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!